Condition: Sickle Cell Disease · Sponsor: New York Medical College
This is a follow-up trial to NYMC 526 (NCT01461837) to assess the safety, efficacy and toxicity of administering Defibrotide prophylaxis for high-risk sickle cell or beta thalassemia patients undergoing a familial haploidentical or MUD allogeneic stem cell transplantation with CD34 enrichment and T-cell addback. This patient population historically has a risk of developing sinusoidal obstructive syndrome (SOS) and Defibrotide has demonstrated efficacy in treatment of SOS. The Funding Source is FDA OOPD.
This description comes directly from the study's public registry record.
Mitchell S Cairo, MD · 914-594-2150 · Mitchell_Cairo@nymc.edu
Erin Morris, RN · 714-964-5359 · erin_morris@nymc.edu
Always discuss trial participation with your own doctor first.
| University of California Los Angeles | Los Angeles, California, United States | Recruiting |
| University of Florida | Gainesville, Florida, United States | Recruiting |
| New York Medical College | Valhalla, New York, United States | Recruiting |
| Medical College of Wisconsin | Milwaukee, Wisconsin, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02675959